Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline

Autores
Arrossi, Silvina; Temin, Sarah; Garland, Suzanne; O'Neal Eckert, Linda; Bhatla, Neerja; Castellsagué, Xavier; Alkaff, Sharifa Ezat; Felder, Tamika; Hammouda, Doudja; Konno, Ryo; Lopes, Gilberto; Mugisha, Emmanuel; Murillo, Rául; Scarinci, Isabel C.; Stanley, Margaret; Tsu, Vivien; Wheeler, Cosette M.; Adewole, Isaac Folorunso; de Sanjosé, Silvia
Año de publicación
2017
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Purpose To provide resource-stratified (four tiers), evidence-based recommendations on the primary prevention of cervical cancer globally. Methods The American Society of Clinical Oncology convened a multidisciplinary, multinational panel of oncology, obstetrics/gynecology, public health, cancer control, epidemiology/biostatistics, health economics, behavioral/implementation science, and patient advocacy experts. The Expert Panel reviewed existing guidelines and conducted a modified ADAPTE process and a formal consensus-based process with additional experts (consensus ratings group) for one round of formal ratings. Results Existing sets of guidelines from five guideline developers were identified and reviewed; adapted recommendations formed the evidence base. Five systematic reviews, along with cost-effectiveness analyses, provided evidence to inform the formal consensus process, which resulted in agreement of ‡ 75%. Recommendations In all resource settings, two doses of human papillomavirus vaccine are recommended for girls age 9 to 14 years, with an interval of at least 6 months and possibly up to 12 to 15 months. Individuals with HIV positivity should receive three doses. Maximal and enhanced settings: if girls are age ‡ 15 years and received their first dose before age 15 years, they may complete the series; if no doses were received before age 15 years, three doses should be administered; in both scenarios, vaccination may be through age 26 years. Limited and basic settings: if sufficient resources remain after vaccinating girls age 9 to 14 years, girls who received one dose may receive additional doses between age 15 and 26 years. Maximal, enhanced, and limited settings: if ‡ 50% coverage in the priority female target population, sufficient resources, and cost effectiveness, boys may be vaccinated to prevent other noncervical human papillomavirus–related cancers and diseases. Basic settings: vaccinating boys is not recommended. It is the view of the American Society of Clinical Oncology that health care providers and health care system decision makers should be guided by the recommendations for the highest stratum of resources available. The guideline is intended to complement but not replace local guidelines.
Fil: Arrossi, Silvina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Instituto Nacional del Cancer; Argentina
Fil: Temin, Sarah. American Society of Clinical Oncology; Estados Unidos
Fil: Garland, Suzanne. University of Melbourne; Australia
Fil: O'Neal Eckert, Linda. University of Washington; Estados Unidos
Fil: Bhatla, Neerja. PATH; Estados Unidos
Fil: Castellsagué, Xavier. L’Hospitalet de Llobregat; España
Fil: Alkaff, Sharifa Ezat. Universiti Kebangsaan; Malasia
Fil: Felder, Tamika. Cervivor; Estados Unidos
Fil: Hammouda, Doudja. Institut National de Santé Publique; Argelia
Fil: Konno, Ryo. Jichi Medical University; Japón
Fil: Lopes, Gilberto. Sylvester Comprehensive Cancer Center; Estados Unidos
Fil: Mugisha, Emmanuel. PATH; Uganda
Fil: Murillo, Rául. International Agency for Research on Cance; Francia
Fil: Scarinci, Isabel C.. University of Alabama at Birmingahm; Estados Unidos
Fil: Stanley, Margaret. University of Cambridge; Reino Unido
Fil: Tsu, Vivien. PATH; Estados Unidos
Fil: Wheeler, Cosette M.. University of New Mexico; Estados Unidos
Fil: Adewole, Isaac Folorunso. Ministry of Health; Nigeria
Fil: de Sanjosé, Silvia. L’Hospitalet de Llobregat; España
Materia
Cervical cancer
HPV vaccination
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/77736

id CONICETDig_5ce315b794bdcb71b381756bd8ff3975
oai_identifier_str oai:ri.conicet.gov.ar:11336/77736
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified GuidelineArrossi, SilvinaTemin, SarahGarland, SuzanneO'Neal Eckert, LindaBhatla, NeerjaCastellsagué, XavierAlkaff, Sharifa EzatFelder, TamikaHammouda, DoudjaKonno, RyoLopes, GilbertoMugisha, EmmanuelMurillo, RáulScarinci, Isabel C.Stanley, MargaretTsu, VivienWheeler, Cosette M.Adewole, Isaac Folorunsode Sanjosé, SilviaCervical cancerHPV vaccinationhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Purpose To provide resource-stratified (four tiers), evidence-based recommendations on the primary prevention of cervical cancer globally. Methods The American Society of Clinical Oncology convened a multidisciplinary, multinational panel of oncology, obstetrics/gynecology, public health, cancer control, epidemiology/biostatistics, health economics, behavioral/implementation science, and patient advocacy experts. The Expert Panel reviewed existing guidelines and conducted a modified ADAPTE process and a formal consensus-based process with additional experts (consensus ratings group) for one round of formal ratings. Results Existing sets of guidelines from five guideline developers were identified and reviewed; adapted recommendations formed the evidence base. Five systematic reviews, along with cost-effectiveness analyses, provided evidence to inform the formal consensus process, which resulted in agreement of ‡ 75%. Recommendations In all resource settings, two doses of human papillomavirus vaccine are recommended for girls age 9 to 14 years, with an interval of at least 6 months and possibly up to 12 to 15 months. Individuals with HIV positivity should receive three doses. Maximal and enhanced settings: if girls are age ‡ 15 years and received their first dose before age 15 years, they may complete the series; if no doses were received before age 15 years, three doses should be administered; in both scenarios, vaccination may be through age 26 years. Limited and basic settings: if sufficient resources remain after vaccinating girls age 9 to 14 years, girls who received one dose may receive additional doses between age 15 and 26 years. Maximal, enhanced, and limited settings: if ‡ 50% coverage in the priority female target population, sufficient resources, and cost effectiveness, boys may be vaccinated to prevent other noncervical human papillomavirus–related cancers and diseases. Basic settings: vaccinating boys is not recommended. It is the view of the American Society of Clinical Oncology that health care providers and health care system decision makers should be guided by the recommendations for the highest stratum of resources available. The guideline is intended to complement but not replace local guidelines.Fil: Arrossi, Silvina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Instituto Nacional del Cancer; ArgentinaFil: Temin, Sarah. American Society of Clinical Oncology; Estados UnidosFil: Garland, Suzanne. University of Melbourne; AustraliaFil: O'Neal Eckert, Linda. University of Washington; Estados UnidosFil: Bhatla, Neerja. PATH; Estados UnidosFil: Castellsagué, Xavier. L’Hospitalet de Llobregat; EspañaFil: Alkaff, Sharifa Ezat. Universiti Kebangsaan; MalasiaFil: Felder, Tamika. Cervivor; Estados UnidosFil: Hammouda, Doudja. Institut National de Santé Publique; ArgeliaFil: Konno, Ryo. Jichi Medical University; JapónFil: Lopes, Gilberto. Sylvester Comprehensive Cancer Center; Estados UnidosFil: Mugisha, Emmanuel. PATH; UgandaFil: Murillo, Rául. International Agency for Research on Cance; FranciaFil: Scarinci, Isabel C.. University of Alabama at Birmingahm; Estados UnidosFil: Stanley, Margaret. University of Cambridge; Reino UnidoFil: Tsu, Vivien. PATH; Estados UnidosFil: Wheeler, Cosette M.. University of New Mexico; Estados UnidosFil: Adewole, Isaac Folorunso. Ministry of Health; NigeriaFil: de Sanjosé, Silvia. L’Hospitalet de Llobregat; EspañaAmerican Society of Clinical Oncology2017-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/77736Arrossi, Silvina; Temin, Sarah; Garland, Suzanne; O'Neal Eckert, Linda; Bhatla, Neerja; et al.; Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline; American Society of Clinical Oncology; Journal of Global Oncology; 3; 5; 10-2017; 611-6342378-9506CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1200/JGO.2016.008151info:eu-repo/semantics/altIdentifier/url/https://ascopubs.org/doi/10.1200/JGO.2016.008151info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T14:59:04Zoai:ri.conicet.gov.ar:11336/77736instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 14:59:04.877CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline
title Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline
spellingShingle Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline
Arrossi, Silvina
Cervical cancer
HPV vaccination
title_short Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline
title_full Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline
title_fullStr Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline
title_full_unstemmed Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline
title_sort Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline
dc.creator.none.fl_str_mv Arrossi, Silvina
Temin, Sarah
Garland, Suzanne
O'Neal Eckert, Linda
Bhatla, Neerja
Castellsagué, Xavier
Alkaff, Sharifa Ezat
Felder, Tamika
Hammouda, Doudja
Konno, Ryo
Lopes, Gilberto
Mugisha, Emmanuel
Murillo, Rául
Scarinci, Isabel C.
Stanley, Margaret
Tsu, Vivien
Wheeler, Cosette M.
Adewole, Isaac Folorunso
de Sanjosé, Silvia
author Arrossi, Silvina
author_facet Arrossi, Silvina
Temin, Sarah
Garland, Suzanne
O'Neal Eckert, Linda
Bhatla, Neerja
Castellsagué, Xavier
Alkaff, Sharifa Ezat
Felder, Tamika
Hammouda, Doudja
Konno, Ryo
Lopes, Gilberto
Mugisha, Emmanuel
Murillo, Rául
Scarinci, Isabel C.
Stanley, Margaret
Tsu, Vivien
Wheeler, Cosette M.
Adewole, Isaac Folorunso
de Sanjosé, Silvia
author_role author
author2 Temin, Sarah
Garland, Suzanne
O'Neal Eckert, Linda
Bhatla, Neerja
Castellsagué, Xavier
Alkaff, Sharifa Ezat
Felder, Tamika
Hammouda, Doudja
Konno, Ryo
Lopes, Gilberto
Mugisha, Emmanuel
Murillo, Rául
Scarinci, Isabel C.
Stanley, Margaret
Tsu, Vivien
Wheeler, Cosette M.
Adewole, Isaac Folorunso
de Sanjosé, Silvia
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Cervical cancer
HPV vaccination
topic Cervical cancer
HPV vaccination
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Purpose To provide resource-stratified (four tiers), evidence-based recommendations on the primary prevention of cervical cancer globally. Methods The American Society of Clinical Oncology convened a multidisciplinary, multinational panel of oncology, obstetrics/gynecology, public health, cancer control, epidemiology/biostatistics, health economics, behavioral/implementation science, and patient advocacy experts. The Expert Panel reviewed existing guidelines and conducted a modified ADAPTE process and a formal consensus-based process with additional experts (consensus ratings group) for one round of formal ratings. Results Existing sets of guidelines from five guideline developers were identified and reviewed; adapted recommendations formed the evidence base. Five systematic reviews, along with cost-effectiveness analyses, provided evidence to inform the formal consensus process, which resulted in agreement of ‡ 75%. Recommendations In all resource settings, two doses of human papillomavirus vaccine are recommended for girls age 9 to 14 years, with an interval of at least 6 months and possibly up to 12 to 15 months. Individuals with HIV positivity should receive three doses. Maximal and enhanced settings: if girls are age ‡ 15 years and received their first dose before age 15 years, they may complete the series; if no doses were received before age 15 years, three doses should be administered; in both scenarios, vaccination may be through age 26 years. Limited and basic settings: if sufficient resources remain after vaccinating girls age 9 to 14 years, girls who received one dose may receive additional doses between age 15 and 26 years. Maximal, enhanced, and limited settings: if ‡ 50% coverage in the priority female target population, sufficient resources, and cost effectiveness, boys may be vaccinated to prevent other noncervical human papillomavirus–related cancers and diseases. Basic settings: vaccinating boys is not recommended. It is the view of the American Society of Clinical Oncology that health care providers and health care system decision makers should be guided by the recommendations for the highest stratum of resources available. The guideline is intended to complement but not replace local guidelines.
Fil: Arrossi, Silvina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Instituto Nacional del Cancer; Argentina
Fil: Temin, Sarah. American Society of Clinical Oncology; Estados Unidos
Fil: Garland, Suzanne. University of Melbourne; Australia
Fil: O'Neal Eckert, Linda. University of Washington; Estados Unidos
Fil: Bhatla, Neerja. PATH; Estados Unidos
Fil: Castellsagué, Xavier. L’Hospitalet de Llobregat; España
Fil: Alkaff, Sharifa Ezat. Universiti Kebangsaan; Malasia
Fil: Felder, Tamika. Cervivor; Estados Unidos
Fil: Hammouda, Doudja. Institut National de Santé Publique; Argelia
Fil: Konno, Ryo. Jichi Medical University; Japón
Fil: Lopes, Gilberto. Sylvester Comprehensive Cancer Center; Estados Unidos
Fil: Mugisha, Emmanuel. PATH; Uganda
Fil: Murillo, Rául. International Agency for Research on Cance; Francia
Fil: Scarinci, Isabel C.. University of Alabama at Birmingahm; Estados Unidos
Fil: Stanley, Margaret. University of Cambridge; Reino Unido
Fil: Tsu, Vivien. PATH; Estados Unidos
Fil: Wheeler, Cosette M.. University of New Mexico; Estados Unidos
Fil: Adewole, Isaac Folorunso. Ministry of Health; Nigeria
Fil: de Sanjosé, Silvia. L’Hospitalet de Llobregat; España
description Purpose To provide resource-stratified (four tiers), evidence-based recommendations on the primary prevention of cervical cancer globally. Methods The American Society of Clinical Oncology convened a multidisciplinary, multinational panel of oncology, obstetrics/gynecology, public health, cancer control, epidemiology/biostatistics, health economics, behavioral/implementation science, and patient advocacy experts. The Expert Panel reviewed existing guidelines and conducted a modified ADAPTE process and a formal consensus-based process with additional experts (consensus ratings group) for one round of formal ratings. Results Existing sets of guidelines from five guideline developers were identified and reviewed; adapted recommendations formed the evidence base. Five systematic reviews, along with cost-effectiveness analyses, provided evidence to inform the formal consensus process, which resulted in agreement of ‡ 75%. Recommendations In all resource settings, two doses of human papillomavirus vaccine are recommended for girls age 9 to 14 years, with an interval of at least 6 months and possibly up to 12 to 15 months. Individuals with HIV positivity should receive three doses. Maximal and enhanced settings: if girls are age ‡ 15 years and received their first dose before age 15 years, they may complete the series; if no doses were received before age 15 years, three doses should be administered; in both scenarios, vaccination may be through age 26 years. Limited and basic settings: if sufficient resources remain after vaccinating girls age 9 to 14 years, girls who received one dose may receive additional doses between age 15 and 26 years. Maximal, enhanced, and limited settings: if ‡ 50% coverage in the priority female target population, sufficient resources, and cost effectiveness, boys may be vaccinated to prevent other noncervical human papillomavirus–related cancers and diseases. Basic settings: vaccinating boys is not recommended. It is the view of the American Society of Clinical Oncology that health care providers and health care system decision makers should be guided by the recommendations for the highest stratum of resources available. The guideline is intended to complement but not replace local guidelines.
publishDate 2017
dc.date.none.fl_str_mv 2017-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/77736
Arrossi, Silvina; Temin, Sarah; Garland, Suzanne; O'Neal Eckert, Linda; Bhatla, Neerja; et al.; Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline; American Society of Clinical Oncology; Journal of Global Oncology; 3; 5; 10-2017; 611-634
2378-9506
CONICET Digital
CONICET
url http://hdl.handle.net/11336/77736
identifier_str_mv Arrossi, Silvina; Temin, Sarah; Garland, Suzanne; O'Neal Eckert, Linda; Bhatla, Neerja; et al.; Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline; American Society of Clinical Oncology; Journal of Global Oncology; 3; 5; 10-2017; 611-634
2378-9506
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1200/JGO.2016.008151
info:eu-repo/semantics/altIdentifier/url/https://ascopubs.org/doi/10.1200/JGO.2016.008151
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv American Society of Clinical Oncology
publisher.none.fl_str_mv American Society of Clinical Oncology
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846083131795308544
score 13.22299